InsidersTradesSigma
Fulcrum Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Fulcrum Therapeutics, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Fulcrum Therapeutics, Inc. has logged 46 public disclosures. Market capitalisation: €247.9m. The latest transaction was reported on 30 June 2026 (Cession). Among the most active insiders: Gould Robert J. The full history is accessible without an account.
46
Insider Decl.
0
Thresholds
€29m
14 ops.
Buy Volume
€1m
12 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Fulcrum Therapeutics, Inc. Hold (neutral), based on 6 analysts. Average price target: US$5.83.
33Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 June 2026
Declarations46 total
18,000 sharesCommon StockSEC:0001193125-26-290622:0
15,000 shares@ US$10.87267.8% of flowCommon StockSEC:0001193125-26-037606
15,000 shares@ US$10.72387.6% of flowCommon StockSEC:0001193125-26-037573
15,000 shares@ US$10.87260.031% mcap7.8% of flowCommon StockSEC:0001193125-26-037606:0
15,000 shares@ US$10.72380.030% mcap7.6% of flowCommon StockSEC:0001193125-26-037573:0
15,000 shares@ US$11.87260.034% mcap8.5% of flowCommon StockSEC:0001193125-26-004572:0
15,000 shares@ US$11.87268.5% of flowCommon StockSEC:0001193125-26-004572
498 shares@ US$5.064.0% of flowCommon StockSEC:0000950170-25-068038:0
8,500,000 sharesCommon StockSEC:0001415889-24-022127:0
150,000 shares@ US$3.2750.0% of flowCommon StockSEC:0000950170-24-081949:0
236 shares@ US$7.763.0% of flowCommon StockSEC:0000950170-24-056947:0
4,884 shares@ US$11.715591.9% of flowCommon StockSEC:0000950170-24-028827:0
43,360 shares@ US$11.347550.0% of flowCommon StockSEC:0000950170-24-025933:0
Ideal exit: 29 Nov 2024 (T+270)
210 shares@ US$3.311.1% of flowCommon StockSEC:0000950170-23-021245:0
1,923,076 shares@ US$13.0080.4% of flowCommon StockSEC:0001104659-23-006213:0
Ideal exit: 17 Oct 2023 (T+270)
6,766 shares@ US$15.005.0% of flowCommon StockSEC:0000899243-23-001803:0
122,334 shares@ US$7.02762.8% of flowCommon StockSEC:0001104659-23-001881:0
Ideal exit: 1 Oct 2023 (T+270)
4,089 shares@ US$5.99410.1% of flowCommon StockSEC:0001104659-22-130982:0
Ideal exit: 23 Sept 2023 (T+270)
98,787 shares@ US$5.89971.9% of flowCommon StockSEC:0001104659-22-129121:0
Ideal exit: 15 Sept 2023 (T+270)
824,600 shares@ US$5.459114.8% of flowCommon StockSEC:0001104659-22-127883:0
Ideal exit: 10 Sept 2023 (T+270)
2,000,000 sharesCommon StockSEC:0000899243-22-038602:0
71,435 shares@ US$7.840.12% mcap29.4% of flowCommon StockSEC:0000899243-22-021530:0
16,689 shares@ US$7.840.027% mcap6.8% of flowCommon StockSEC:0000899243-22-021250:0
3,250 shares0Common StockSEC:0000899243-22-017416:0
5,631 shares@ US$7.840.0091% mcap2.3% of flowCommon StockSEC:0000899243-22-014438:0
25 of 46 declarations
About Fulcrum Therapeutics, Inc.
Geographically, Fulcrum’s operating footprint is concentrated in the Boston/Cambridge biotech cluster, where it maintains its headquarters and laboratory space. That location provides access to talent, academic networks, and the broader U.S. life sciences ecosystem, but the company remains primarily a research and development organization with limited commercial infrastructure. Recent highlights include positive updates from the Phase 1b PIONEER study of pociredir in SCD, plans to advance toward a potential registration-enabling trial in the second half of 2026, and a stronger cash position at the end of 2025 following a public equity offering. Overall, Fulcrum remains a high-risk, high-upside rare-disease biotech listed on the NASDAQ Global Market in the United States.
